Intravesicular Abraxane for Treatment-Refractory Bladder Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

March 31, 2013

Study Completion Date

February 28, 2014

Conditions
Bladder Cancer
Interventions
DRUG

Abraxane

"Abraxane is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Intravesically administered, dose escalation, 6 weekly instillations"

Trial Locations (1)

10032

Herbert Irving Pavillion 11th Floor, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Columbia University

OTHER